antibody-drug conjugate PHN-010
Term · Oncology and biomedicine · MLC-T-ONC-010180
An antibody-drug conjugate (ADC) composed of an as of yet undisclosed monoclonal antibody directed against a tumor-associated antigen (TAA) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of ADC PHN-010 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an as of yet unknown mechanism of action.
| Identifier | MLC-T-ONC-010180 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | ADC PHN-010 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-010180",
"term": "antibody-drug conjugate PHN-010",
"field": "Oncology and biomedicine",
"definition": "An antibody-drug conjugate (ADC) composed of an as of yet undisclosed monoclonal antibody directed against a tumor-associated antigen (TAA) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of ADC PHN-010 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an as of yet unknown mechanism of action.",
"synonyms": [
"ADC PHN-010"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/antibody-drug-conjugate-phn-010/"
}
Record 1,260 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.